Tests TER-2013 in advanced solid tumors with PI3K pathway changes

Trial details

Who runs it

Terremoto Biosciences Inc.

Trial code

NCT07109726

Record updated

28 October 2026

Original description

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.Read full original descriptionShow less

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

Inclusion: Metastatic or locally advanced, unresectable disease; No available treatment with curative intent; Presence of lesions to be evaluated per RECIST v1.1:; Dose Escalation: measurable or evaluable disease b. Cohort Expansion: measurable disease; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Adequate organ function; Advanced solid tumor malignancy harboring an eligible AKT/PI3K/PTEN pathway alteration detected by a sponsor approved test; Histologically confirmed diagnosis of:; [For TER-2013 dose escalation]: solid tumor malignancy b. [For TER-2013 cohort expansion]: i. Cohort 1: ovarian cancer, cervical cancer, or squamous cell carcinoma of the head and neck, lung, or esophagus ii. Cohort 2: endometrial adenocarcinoma; Prior therapy:; [For TER-2013 dose escalation]: Received standard therapies appropriate for their tumor type and stage, unless contraindicated, intolerable, or patient refused; [For TER-2013 cohort expansion]: No more than 3 prior lines of treatment in the advanced setting; Histologically confirmed diagnosis of:; [For TER-2013 + fulvestrant dose escalation]: HR+/HER2- advanced unresectable or metastatic breast cancer b. [For TER-2013 + fulvestrant cohort expansion]: i. Received treatment with an AI containing regimen (single agent or in combination), CDK4/6 inhibitor, and PARP inhibitor (if germline BRCA-mutated) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting; Prior Therapy:; [For TER-2013 + fulvestrant dose escalation]: Received treatment with an AI containing regimen (single agent or in combination) b. [For TER-2013 + fulvestrant cohort expansion]: i. Received treatment with an AI containing regimen (single agent or in combination), CDK4/6 inhibitor, and PARP inhibitor (if germline BRCA-mutated) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting.

Exclusion: History of significant hemoptysis or hemorrhage within 4 weeks prior to first dose of study drug; Prior therapy:; [For TER-2013 monotherapy escalation]: AKT inhibitor; [For TER-2013 monotherapy expansion]: AKT/PI3K/PTEN pathway inhibitor; [For TER-2013 + fulvestrant combination expansion]: AKT/PI3K/PTEN pathway inhibitor, fulvestrant and other SERDs, mTOR inhibitor; some PIK3CA-altered cohorts allow prior PI3K inhibitor; Other protocol-defined Inclusion/Exclusion Criteria apply; Malabsorption syndrome, nausea and vomiting uncontrolled by medication, or disease significantly affecting gastrointestinal function likely to interfere with the delivery, absorption, or metabolism of TER-2013; Known EGFR, KRAS, NRAS, HRAS, or BRAF oncogenic-driver co-mutation with PI3K/AKT/PTEN alteration; Clinically significant abnormalities of glucose metabolism; Active brain metastases or carcinomatous meningitis.

ClinicalTrials.gov NCT07109726